{"id":31005,"date":"2024-04-23T11:09:49","date_gmt":"2024-04-23T11:09:49","guid":{"rendered":"https:\/\/new.tabukpharmaceuticals.com\/?p=31005"},"modified":"2025-06-10T13:39:13","modified_gmt":"2025-06-10T13:39:13","slug":"tabuk-and-hk-inno-n-partner-to-bring-k-cabtegoprazan-an-innovative-medicine-to-the-mena-region","status":"publish","type":"post","link":"https:\/\/www.tabukpharmaceuticals.com\/ar\/tabuk-and-hk-inno-n-partner-to-bring-k-cabtegoprazan-an-innovative-medicine-to-the-mena-region\/","title":{"rendered":"\u062a\u0628\u0648\u0643 \u0648 HK INNO.N \u062a\u062a\u0639\u0627\u0648\u0646\u0627\u0646 \u0644\u062a\u0642\u062f\u064a\u0645 \u062f\u0648\u0627\u0621 K-CAB\u00ae (\u062a\u064a\u063a\u0648\u0628\u0631\u0627\u0632\u0627\u0646) \u0627\u0644\u0645\u0628\u062a\u0643\u0631 \u0625\u0644\u0649 \u0645\u0646\u0637\u0642\u0629 \u0627\u0644\u0634\u0631\u0642 \u0627\u0644\u0623\u0648\u0633\u0637 \u0648\u0634\u0645\u0627\u0644 \u0623\u0641\u0631\u064a\u0642\u064a\u0627."},"content":{"rendered":"

Riyadh<\/strong> \u2013 Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group), a leading Saudi pharmaceuticals company, announced today an exclusive license agreement with HK inno.N<\/strong>, a leading Korean pharmaceuticals company, to commercialize Tegoprazan<\/strong>, a novel potassium-competitive acid blocker (P-CAB), which is regarded as the next-generation treatment for gastroesophageal reflux disease (GERD)<\/strong> and other acid-related conditions in the Middle East region<\/strong>.<\/p>\n\n\n\n

Under the agreement, Tabuk has the exclusive rights for commercialization and marketing of K-CAB\u00ae (Tegoprazan)<\/strong> in the Middle East and North Africa<\/strong>.<\/p>\n\n\n\n

K-CAB\u00ae (Tegoprazan) has also been licensed out to 35 countries including the US<\/strong>, and K-CAB is set to become the first potential Korean global blockbuster drug<\/strong> in the pharmaceutical industry, with ongoing Phase 3 clinical trials in the US advancing at a timely rate<\/strong>.<\/p>\n\n\n\n

Since its launch in 2019, K-CAB\u00ae<\/strong>, considered Korea\u2019s 30th new drug<\/strong>, has been ranked the No.1 gastroesophageal reflux disease drug for 4 consecutive years<\/strong> in the Korean market.<\/p>\n\n\n\n

Kwak Dal-won<\/strong>, CEO of HK inno.N, said,<\/p>\n\n\n\n

\n

\u201cThrough this expansion into the MENA region, K-CAB\u00ae has established footprints in the pharma emerging markets of Southeast Asia, Central and South America, the Middle East, and North Africa.\u201d<\/p>\n<\/blockquote>\n\n\n\n

Song Geun-seok<\/strong>, Vice President of HK inno.N, also said,<\/p>\n\n\n\n

\n

“We will accelerate our global business to enter 100 countries by 2028 and achieve global sales of 2 trillion won by 2030.”<\/p>\n<\/blockquote>\n\n\n\n

Ismail Shehada<\/strong>, CEO of Tabuk, added,<\/p>\n\n\n\n

\n

\u201cAs part of our role and mission in Tabuk to deliver unique health solutions to people of Saudi Arabia and remaining MENA countries, our partnership with HK inno.N comes in as an evident choice to further support our mission in line with Saudi Vision 2030 regarding innovation.\u201d<\/p>\n<\/blockquote>\n\n\n\n

Wisam Alkhatib<\/strong>, Chief Business Development Officer at Tabuk, said,<\/p>\n\n\n\n

\n

\u201cThis partnership builds on our strategy to expand our specialty and innovative business and reinforces our leading position in the gastrointestinal market with this new class of medicine.\u201d<\/p>\n<\/blockquote>\n\n\n\n

\n\n\n\n

About Tegoprazan<\/h3>\n\n\n\n

Tegoprazan is a novel P-CAB<\/strong> for the treatment of EE<\/strong>, a chronic and progressive condition that impacts millions of patients worldwide. It is designed to block proton pumps<\/strong> from secreting gastric acid in the stomach.<\/p>\n\n\n\n

P-CABs<\/strong> have been shown to act more rapidly and suppress the secretion of acid more effectively and more durably than proton pump inhibitors (PPIs)<\/strong>.<\/p>\n\n\n\n

Tegoprazan, as a potassium-competitive acid blocker (P-CAB)<\/strong>, is regarded as the next-generation treatment<\/strong> to replace PPIs<\/strong>, often used for GERD<\/strong>.<\/p>\n\n\n\n

Over 80 clinical studies<\/strong> are either in progress or have been completed, and 60+ theses<\/strong> have been published in renowned journals in Korea and overseas.<\/p>\n\n\n\n

With extensive studies on indications, K-CAB carries the most indications among P-CAB drugs in Korea<\/strong>. Moreover, the company addressed administration convenience<\/strong> by developing the ODT (orally disintegrated tablet)<\/strong> formulation and is also developing injections for emergency patients<\/strong>.<\/p>\n\n\n\n

\n\n\n\n

About Tabuk<\/h3>\n\n\n\n

Tabuk Pharmaceutical Manufacturing Company<\/strong> is a leading Saudi pharmaceutical company with a regional presence in the Middle East and North Africa<\/strong>.<\/p>\n\n\n\n

Tabuk Pharmaceuticals develops, manufactures, markets, and distributes various branded generics<\/strong>, in addition to manufacturing pharmaceutical products for renowned international partners at its manufacturing sites in Saudi Arabia, as part of its continuous efforts to cover the needs of patients by providing high-quality medicines<\/strong>.<\/p>\n\n\n\n

Tabuk Pharmaceuticals is a major player in the pharmaceutical sector not only in the Kingdom of Saudi Arabia<\/strong>, but also across MENA<\/strong>, thanks to its four state-of-the-art manufacturing sites<\/strong> located in Tabuk and Dammam<\/strong> in the Kingdom, as well as in Sudan and Algeria<\/strong>, and orchestrated by a team of more than 2,400 employees<\/strong>.<\/p>\n\n\n\n

Tabuk Pharmaceuticals reaches patients in 17 countries<\/strong> in the Middle East and Africa, with futuristic plans<\/strong> to expand its presence in the region.<\/p>\n\n\n\n

\n\n\n\n

About HK inno.N<\/h3>\n\n\n\n

HK inno.N<\/strong> was established as CJ CheilJedang Pharmaceutical Business Department in 1984<\/strong> and launched as CJ Healthcare in 2014<\/strong>. It was incorporated into Kolmar Group in 2018<\/strong> and changed its name to HK inno.N in 2020<\/strong>.<\/p>\n\n\n\n

HK inno.N has technology-oriented business competitiveness<\/strong> in the field of prescription drugs and Health & Beauty<\/strong>, under the mission of \u2018Heal the World for a Better Life\u2019<\/em>.<\/p>\n\n\n\n

In the field of prescription drugs, it is focusing its capabilities on developing innovative drugs with high market value<\/strong>, based on its ability to develop Korea’s 30th novel drug \u2018K-CAB\u00ae\u2019<\/strong> and grow it into a blockbuster novel drug<\/strong>.<\/p>","protected":false},"excerpt":{"rendered":"

Riyadh \u2013 Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group), a leading Saudi pharmaceuticals company, announced today an exclusive license agreement with HK inno.N, a leading Korean pharmaceuticals company, to commercialize Tegoprazan, a novel potassium-competitive acid blocker…<\/p>","protected":false},"author":6,"featured_media":31006,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-31005","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/posts\/31005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/comments?post=31005"}],"version-history":[{"count":3,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/posts\/31005\/revisions"}],"predecessor-version":[{"id":31394,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/posts\/31005\/revisions\/31394"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/media\/31006"}],"wp:attachment":[{"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/media?parent=31005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/categories?post=31005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/tags?post=31005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}